Stockscreener 앱 받기
27.68
4.65%
1.23
시간 외 거래:
28.50
0.82
+2.96%
Zenas Biopharma Inc 주식(ZBIO)의 최신 뉴스
ZBIOZenas Biopharma Inc Earnings - Finviz
Zenas Wins Dismissal Of IPO Suit Over R&D Spending Claims - Law360
Zenas BioPharma Shakes IPO Investor’s Cash Burn Rate Lawsuit - Bloomberg Law News
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to Russell 2500 Growth Benchmark - marketscreener.com
Zenas BioPharma, Inc.(NasdaqGS:ZBIO) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) dropped from Russell 2000 Value Benchmark - marketscreener.com
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to Russell 2000 Growth Benchmark - marketscreener.com
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to Russell 3000E Growth Benchmark - marketscreener.com
Does Zenas BioPharma (ZBIO) Shifting Into Russell Growth Indices Recast Its Core Investment Story? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Join Class Action to Recover Losses from Zenas BioPharma, Inc. (Z - The National Law Review
ZBIO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Investor Alert: Deadline Approaching to Join Zenas BioPharma, Inc. (ZBIO) Class ActionContact Levi & Korsinsky - The National Law Review
Levi & Korsinsky Notifies Zenas BioPharma, Inc. (ZBIO) Investors - The National Law Review
H.C. Wainwright Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $44 - Moomoo
ZBIO DEADLINE NOTICE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm - TMX Newsfile
Zenas BioPharma, Inc. Actuals & Estimates (NASDAQ:ZBIO) - TradingView
Enterprise value to EBITDA forward of Zenas BioPharma, Inc. – BOATS:ZBIO - TradingView
Enterprise value to revenue forward of Zenas BioPharma, Inc. – NASDAQ:ZBIO - TradingView
ZBIO Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Zenas BioPharma, Inc. – BOATS:ZBIO - TradingView
Price to book forward of Zenas BioPharma, Inc. – BOATS:ZBIO - TradingView
Zenas Biopharma Inc (ZBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zenas Biopharma Inc (ZBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction. - The Motley Fool
Zenas Biopharma Inc (ZBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zenas Biopharma Inc (ZBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zenas Biopharma Inc (ZBIO) Institutional Confidence - TradingKey
Zenas Biopharma Inc (ZBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zenas Biopharma Inc (ZBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Director at Zenas BioPharma (ZBIO) receives 18,500 stock options at $18.71 strike - Stock Titan
Zenas BioPharma (ZBIO) director awarded 500K stock options at $18.71 - Stock Titan
Zenas BioPharma (ZBIO) director awarded 18,500 stock options at $18.71 - Stock Titan
Zenas BioPharma (ZBIO) awards 18,500 stock options to director Orloff - Stock Titan
Zenas BioPharma (ZBIO) awards 150,000 stock options to officer - Stock Titan
Director at Zenas BioPharma (ZBIO) receives 18,500 stock options grant - Stock Titan
Zenas BioPharma (ZBIO) director awarded 18,500 options at $18.71 - Stock Titan
Zenas BioPharma (ZBIO) awards stock options and ESPP shares to officer - Stock Titan
Zenas BioPharma (ZBIO) awards options and ESPP shares to officer - Stock Titan
Zenas Biopharma Inc (ZBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zenas Biopharma Inc (ZBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
ZBIO: Obexelimab nears launch for IgG4-RD, with a robust neuro-immunology pipeline advancing - TradingView
Zenas BioPharma (ZBIO) Is Up 13.3% After Strong Obexelimab Phase 3 Data And FDA BLA Filing - Sahm
Why is Zenas BioPharma stock rallying 9% today? By Investing.com - Investing.com Canada
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - The Manila Times
Zenas BioPharma (ZBIO) Revenue BreakdownMain Composition - Moomoo
Guggenheim Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $55 - Moomoo
H.C. Wainwright reiterates Zenas Biopharma stock rating at buy By Investing.com - Investing.com Canada
Zenas BioPharma reports positive phase 3 trial results for obexelimab By Investing.com - Investing.com India
1.17%
2.48%
자본화:
|
볼륨(24시간):